Amneal Pharmaceuticals (AMRX) Jefferies Global Healthcare Conference summary

Company history and leadership

• Founded in 2002, grew privately until 2017, merged with Impax, and became public in 2018.

• Founders returned as CEOs in 2019 and maintain majority ownership.

Industry trends and strategy

• Generic drugs fill 92% of US prescriptions, with growing demand due to aging populations.

• Price erosion has challenged the sector, but investment in quality and new technologies is ongoing.

• Focus on affordable access, with 280+ products and a pipeline of 100, including biosimilars and specialty drugs.

Addressing drug shortages and product launches

• Introduced 13 products to alleviate US drug shortages, with plans for 20-30 more.

• Maintains a 97-98% fill rate and a strong quality record.

• Plans to launch 30-40 new molecules annually across small molecules, biosimilars, and specialty products.